194: A molecular profile of endothelial cell-derived growth factors that regulate stem cell self-renewal  by Himburg, H. et al.
Huddinge, Stockholm, Sweden; 5Karolinska Institutet, Department of
Laboratory Medicine, Stockholm, Sweden.
Cyclophosphamide (CPA) is used for the treatment of many
tumors and as a part of the conditioning regimen prior to stem cell
transplantation. CPA is a prodrug that is activated through cyto-
chrome P450 2B6 (CYP2B6) in the liver. A high degree of inter-
and intra-individual variation in CPA pharmacokinetics has been
reported. We have investigated the formation of its active metab-
olite 4-hydroxycyclophosphamide (4-OH-CPA) in vitro using
three different mutants of recombinant 2B6. The rate of formation
of 4-OH-CPA was correlated to the enzyme activity for different
mutations. Different concentrations of CPA (0-10 mM) have been
incubated with microsomes from yeast cells expressing human
CYP2B6*1 and the alleles *4, *6 as well as the point mutation
G516T. The lowest Km was observed in wild type 2B6 which also
gave the lowest Vmax (0.884 mM and 175 pmol/min/pmol P450,
respectively). The ratio of Vmax/Km was 3-4 fold higher with
CYP2B6*1 than with any of the mutants (*4, *6 and G516T).
These results did not correlate with clinical data where patients,
with hematological malignancies, having the CYP2B6 G516T mu-
tation have been shown by Xie et al to have higher rates of CPA
4-hydroxylation. In vitro, however, all three mutant alleles were
shown to have less CPA 4-hydroxylase activity than CYP2B6*1,
possibly due to the high reductase activity of the cDNA-expressed
CYP2B6*1 used as wild type for comparison.
In this paper, we propose that the discrepancy seen may depend
on the ratio between the expressed levels of NADPH-cytochrome
P450 reductase and cytochrome P450 in the cells used, especially
in those expressing CYP2B6*1. Very high reductase to P450 ratios
could enhance fast reactions, like CPA 4-hydroxylation, where the
electron transfer may be rate limiting. The ratios in the micro-
somes used are not physiologically relevant and points out one
difﬁculty in scaling from in vitro to in vivo. To evaluate the effect
of the relative amount of reductase, we also used efavirenz as a slow
substrate for CYP 2B6. Our results showed similar activity for the
mutated enzymes for efavirenz compare the clinical data in HIV-1
patients, less enzyme activity of mutants G516T and *6 involved in
efavirenz metabolism compare to wild type and also less activity
was observed for *4. We concluded that the polymorphism of the
CYP2B6 gene will inﬂuence the CPA metabolism and that it may
be important to determine the genotype of the patients before
starting treatment.
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TPO INDUCES HEMATOPOIETIC DIFFERENTIATION OF HUMAN ES
CELLS
Srivastava, A.S.1, Nedelcu, E.2, Mishra, R.3, Carrier, E.1 1University
of California Medical Center, La Jolla, CA; 2UCLA-Harbor, Los An-
geles, CA; 3Case Western University, Cleveland, OH.
Recently, it was demonstrated that TPO enhances hematopoietic
differentiation of primate ES cells, but its role in differentiating
human ES cells is unknown. Therefore, we sought to investigate
the regulatory mechanism of TPO induced signals mediated by the
c-mpl cytoplasmic domain during human embryonic stem (hES)
cells hematopoietic commitment. We hypothesize that in human
embryonic stem cells, binding of TPO to its c-mpl receptor causes
three-dimensional alterations which bring the c-mpl cytoplasmic
domain and Janus Kinase into close-proximity and thus induces the
phosphorylation and dimerization of STAT5 molecule. Dimerized
STAT5 molecules detach from the receptors and migrate to the
nucleus where they bind GAS site and induce transcription of a set
of target, hematopoiesis-related genes. NIH human ES cell lines
(WI01) were used. In brief, to achieve EB formation, cells were
incubated in differentiation medium, which consisted of knockout
DMEM medium (GIBCO/BRL, Carlsbad, USA), supplemented
with 20% non-heat-inactivated fetal bovine serum (FBS, Hyclone,
USA), 1% nonessential amino acids, 1 mM L-glutamine, and 0.1
mM 	-mercaptoethanol. Subsequently, DMEM was replaced by
IMDM (GIBCO/BRL, USA) with the same supplements and ad-
ditional two cytokines (100 ng/mL SCF and 100 ng/mL Flt-3
ligand (Flt-3L)) (control group). To investigate the role of TPO
and VEGF, cells were additionally treated with 100 ng/mL TPO
alone or in combination with 100 ng/mL rhVEGF. All cytokines
were from the R&D systems (USA). There was a signiﬁcant in-
crease in the numbers of embryoid bodies (EBs) formation in TPO
(125/105), TPO/VEGF (150/105 cells) when compared to controls
(10/105 planted ES cells). This corresponded to the increase in
CFU-C and speciﬁc progenitors (CD31/CD34 positive) and in
hematopoietic (CD34-positive cells) cells. Analysis of gene expres-
sion during hematopoietic development demonstrated that TPO/
VEGF combination increased mRNA expression of the TPO re-
ceptor (TPO-R) and VEGF (VEGF-R) receptors in hematopoietic
progenitors as well as CD34 cells. We are in the process of
determining the role of JAK/STAT pathway .in this process. Func-
tional studies will involve blocking of TPO/c-mpl using TPO-R-
speciﬁc antibodies and determining its impact on human ES-
derived hematopoiesis.
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INTESTINAL TISSUE ENGINEERING: A PRELIMINARY STUDY OF LONG
TERM IN VITRO PRIMARY CULTURE OF INTESTINAL EPITHELIAL CELLS
Gandia, C.1, David, A.1, Santiago, S.1, Ruiz, P.2, Tzakis, A.1,
Kleiner, G.1 1Department of Surgery, University of Miami, Miami, FL;
2Department of Pathology, University of Miami, Miami, FL.
Clinical conditions of the small bowel such as congenital or
surgical resection may affect the functional capability of the mu-
cosal lining of the intestinal tract. Despite recent advances in small
bowel transplantation, organ shortages remain an issue. Models
that mimic the intestinal niche provide opportunities to evaluate
stem cell development. Neointestinal engineering from intestinal
epithelial organoid units (IEOU) may be a potential alternative
therapy to solve the problems of acute organ shortage and rejection
in short bowel syndrome (SBS) patients. A novel in vitro enzymatic
digestion method to simulate the intestinal stem cell niche was
developed in a rat system. Citrulline, an amino acid exclusively
synthesized by intestinal epithelial cells, was analyzed in a primary
culture for up to 100 days. Three distinct periods of citrulline levels
were observed in the culture system. A strong correlation between
citrulline and lactate was demonstrated. Addition of rodent bone
marrow derived mesenchymal cells increased citrulline synthesis
following long term culture. This cellular niche model and the
inﬂuence of non-hematopoietic cells should have utility in tissue
engineering projects.
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A MOLECULAR PROFILE OF ENDOTHELIAL CELL-DERIVED GROWTH
FACTORS THAT REGULATE STEM CELL SELF-RENEWAL
Himburg, H.1, Muramoto, G.G.1, Salter, A.B.1, Zhai, J.1,
Chi, J.-T.A.1, Chute, J.P.1 1Duke University Medical Center, Durham,
NC.
Several molecular pathways that regulate hematopoietic stem cell
(HSC) self-renewal in the mouse have recently been elucidated,
including Notch, HOXB4, Wnt and bone morphogenetic protein
signaling pathways. However, full elucidation of the intrinsic and
extrinsic mechanisms that regulate human HSC self renewal has
yet to be realized. As a model for identifying extrinsic factors that
stimulate human HSC self-renewal, we have studied the capacity
for vascular endothelial cells to support human HSC expansion ex
vivo. We have found that primary human brain-derived endothelial
cells (HUBECs), unlike all other tissue sources of human ECs we
have studied, support a 1-2 log ampliﬁcation of human bone
marrow and cord blood HSCs in short term culture, in the absence
of contact (Blood 105:576-83, Blood 100:4433-39). These results
indicate that HUBECs are an ideal resource to identify novel
soluble growth factors that trigger human HSC self-renewal and
expansion. In this study, we applied a comprehensive gene expres-
sion strategy to identify the secreted gene products differentially
expressed by HUBECs as compared to ECs from a wide range of
non-brain tissues, including aorta, pulmonary artery, iliac artery,
dermal artery and coronary artery. RNA was isolated from 9
different non-brain ECs and 6 different HUBECs, each of which
has been shown by our laboratory to promote human HSC expan-
sion in vitro. Samples were hybridized to Operon Human v.3
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oligonucleotide arrays. Applying both an unsupervised hierarchical
clustering analysis and a supervised Bayesian ANOVA analysis, 300
genes from these analyses were classiﬁed as being either membrane
bound or soluble gene products based on the database of mem-
brane-associated/soluble gene products generated by Diehn et al.
(PLoS Genetics epub 2006). Thirty-two of these were annotated to
be secreted gene products. Several novel growth factors not typi-
cally associated with hematopoiesis were identiﬁed. We have found
that one of these factors, adrenomedullin, a vasodilator not known
to have hematopoietic function, induces the proliferation of human
BM CD34CD38-lin- HSCs in single cell cultures and promotes
the quantitative expansion of human BM CD34 progenitor cells
in vitro. This molecular signature of HUBECs provides a unique
resource for the discovery and characterization of novel soluble
factors that regulate human HSC fate.
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FLT3 EXPRESSION DISCRIMINATES HSC SUBPOPULATIONS WITH DIF-
FERING ENGRAFTMENT-POTENTIAL
Huang, Y.1, Ratajczak, M.Z.2, Reca, R.2, Xu, H.1, Tanner, M.1,
Rezzoug, F.1, Hussain, L.-R.1, Fugier-Vivier, I.1, Bolli, R.3,
Ildstad, S.T.1 1Institute for Cellular Therapeutics, Louisville, KY; 2Stem
Cell Biology Program, James Graham Brown Cancer Center, Louisville,
KY; 3Division of Cardiology, University of Louisville, Louisville, KY.
HSC, sorted as KSL (c-KitSca-1Lin-) cells, are comprised of
primitive long-term repopulating cells and short-term repopulat-
ing committed progenitors. Growth factors such as GM-CSF,
G-CSF or Flt3-ligand (FL) are utilized to expand and mobilize
HSC. We evaluated here the phenotype and function of FL-
mobilized HSC. FL signiﬁcantly expands c-Kithi and c-Kitlo KSL
cells in peripheral blood (PB). Only FL-expanded PB c-Kithi KSL
cells exhibited high spleen colony-forming unit frequency, gener-
ated high numbers of both lymphoid and myeloid colonies in vitro,
and rescued ablated recipients. FL expanded two subsets of c-Kithi
KSL cells: CD34ﬂt3- reﬂective of short-term HSC (ST-HSC)
and CD34-ﬂt3- long-term HSC (LT-HSC), while the proportion
of c-Kithi CD34ﬂt3 KSL cells multipotent progenitors (MPP)
was signiﬁcantly decreased in the PB. When 500 CD34ﬂt3-,
CD34ﬂt3 or CD34-ﬂt3- c-Kithi KSL cells were transplanted
into ablated syngeneic recipients, all recipients of CD34ﬂt3
c-Kithi KSL expired within 16 days (n 5). One of the 5 recipients
of c-Kithi CD34ﬂt3- KSL (ST-HSC) survived over 120 days. The
combination of 50 c-Kithi CD34-ﬂt3- KSL cells (LT-HSC) with
500 c-Kithi CD34ﬂt3- or CD34ﬂt3 KSL cells enhanced recip-
ient survival (4/6 recipients of both ST-HSC plus LT-HSC sur-
vived over 120 days and some recipients of MPP  LT-HSC
survived up to 68 days ). These data suggest that ﬂt3 expression
may be a useful phenotypic marker for selecting critical stem cell
populations to ensure rapid and durable engraftment and conﬁrms
that both short and long-term repopulating cells are needed for
optimal successful transplantation.
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ABILITY OF ANTI C-KIT TARGETING MONOCLONAL ANTIBODY ACK-2
TO TARGET HEMATOPOIETIC STEM CELLS, AND FACILITATE ENGRAFT-
MENT OF HUMAN CD34 ENGRAFTMENT AND HEMATOLYMPHOID
DEVELOPMENT IN IMMUNODEFICIENT MICE: A NOVEL ANTIBODY
BASED CONDITIONING STRATEGY
Kraft, D.L.1, Czechowicz, A.1, Bhattacharya, D.1, Weissman, I.L.1
1Stanford University School of Medicine, Stanford, CA.
INTRODUCTION: The stem cell receptor factor receptor,
c-Kit, is expressed on hematopoeitic stem (HSC) and progenitor
cell populations and may serve as a target molecule for manipula-
tion of host HSC & their niche. ACK2 is an anti-mouse c-Kit mAb
which has been shown to antagonize the function of c-kit and
deplete the bone marrow. We wished to characterize the effect &
kinetics of ACK2 on blood cell counts and marrow hematopoetic
stem cell (HSC) and progenitor populations. We also sought to
test the hypothesis that treatment with an HSC targeting mAb may
serve as an novel antibody based conditioning strategy as well as a
means for enhancing human HSC engraftment in immunodeﬁ-
cient mice by selectively inhibiting murine HSC.
METHODS: Adult C57/BL mice were injected with anti
1-500ug of ACK2 mAb & peripheral blood counts, as well as
marrow HSC and progenitor frequency were followed. Subse-
quently, we examined the ability of ACK2 to enhance human
engraftment in sublethally irradiated (4Gy) immunodeﬁcient
RAG2/Common Gamma-Chain double knock out (RAG2-DKO)
pups injected intrahepatically with 1-510^5 CD34 cells from
human mobilized peripheral blood (hCD34).
RESULTS: Administration of ACK2 resulted in rapid develop-
ment of anemia, neutropenia & thrombocytopenia. In treated
mice, the mean number & bone marrow fraction of Long-Term
HSC decreased markedly from .07% of total marrow cells in
controls to .003% in ACK2 treated mice as did the marrow num-
ber/frequency of CMP, GMP, and CMP. Human CD34 trans-
planted RAG-2 DKO mice treated with ACK2 engrafted at a
higher rate (46% vs 27% of controls achieved 10% human
chimerism) with higher human CD45 chimerism in blood, bone
marrow, spleen, liver, & lymph nodes. Robust human thymopoeisis
was observed with a mean of 63% of cells within the thymus
human derived. We found differentiation of mature human T-cells
occured via a CD3-48- intermediate a pathway identical to that
which we found in human stroma in SCID-hu T-cell development.
The ability for host ACK2 conditioning alone to enable donor
murine HSC engraftment will be presented.
CONCLUSIONS: Anti c-kit mAb treatment rapidly induces
pancytopenia with correlating decreases in the numbers of marrow
HSC and other progenitor populations and may serve as a strategy
for host HSC targeted mAb based conditioning. ACK-2 enhances
the frequency and degree of human CD34 engraftment and
human thymopoiesis and may serve as a means to enhance this new
model of human hematopoiesis.
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MUTATED HOXB4 RESULTS IN INCREASED INTRACELLULAR STABILITY
AFFECTING BOTH LONG AND SHORT TERM HEMATOPOIETIC RECON-
STITUTION
Beauchemin, S.1, Krosl, G.1, Nathalie, B.2, Krosl, J.2, Sauvageau, G.1,2,
Roy, D.C.1,2 1Hopital Maisonneuve-Rosemont Research Center, Mon-
treal, QC, Canada; 2Research Institute for Immunology and Cancer,
Montreal, QC, Canada.
The capacity of recombinant Hoxb4 protein to induce ex vivo
expansion of hematopoietic stem cells (HSCs) identiﬁes this pro-
tein as a potential HSC expanding factor. However, its short extra-
and intra-cellular half-life (3-4 hours and 40-60 minutes, respec-
tively) hampers clinical applications of Hoxb4. The analyses of
Hoxb4 molecular structure lead us to generate amino acid substi-
tutions: (A) Leu73Ala, (B) Tyr233Ala and (C) Tyr283Ala in
the Hoxb4 protein in order to promote its stability. Indeed, these
modiﬁcations increased the intracellular stability of Hoxb4 protein
3-fold compared to wild type Hoxb4 (Hoxb4(WT)). The ability
of mutated Hoxb4 protein to favor expansion of hematopoietic
progenitors was ﬁrst examined in cultures initiated with 10%
Hoxb4(WT)-GFP, 10% mutated Hoxb4-YFP expressing cells and
80% non-transduced cells. After an 18-day culture, the proportion
of A and B Hoxb4 mutants cells increased to 50-60% in compar-
ison to 30% for Hoxb4(WT) (p 0.05), and no difference between
the proliferation of C Hoxb4 mutant and Hoxb4(WT) cells could
be identiﬁed. Western blot analyses showed that the A and B
Hoxb4 mutants expressed  4-fold higher and C Hoxb4 mutant
cells  8-fold lower levels of Hoxb4 protein than Hoxb4(WT)
cells. The long-term reconstituting ability of these constructs was
then evaluated in vivo using competitive repopulation assays. At 8
and 16 weeks after transplantation, A and B Hoxb4 mutants con-
tributed less peripheral blood and BM leukocytes (PBL) than
Hoxb4(WT). Flow cytometry analysis of bone marrow, spleen and
thymus revealed that mutated Hoxb4, like Hoxb4(WT) was ex-
pressed by all hematopoietic lineages, and that repopulation dif-
ferences observed between mutated and WT Hoxb4 expressing
cells were almost entirely attributable to myeloid lineage cells.
However, non-competitive repopulation experiments showed that
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